See more : Create SD Holdings Co., Ltd. (3148.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zydus Lifesciences Limited (CADILAHC.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zydus Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Canara Bank (CANBK.NS) Income Statement Analysis – Financial Results
- DV Biomed Co., Ltd. (6539.TWO) Income Statement Analysis – Financial Results
- Inox Wind Limited (INOXWIND.BO) Income Statement Analysis – Financial Results
- EDION Corporation (2730.T) Income Statement Analysis – Financial Results
- NEXGEL, Inc. (NXGL) Income Statement Analysis – Financial Results
Zydus Lifesciences Limited (CADILAHC.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zyduslife.com/zyduslife/
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.51B | 150.63B | 142.87B | 140.27B | 129.29B | 115.99B | 94.30B | 98.38B | 86.51B | 72.24B | 63.58B | 50.90B | 44.65B | 36.87B | 28.62B | 22.66B | 17.86B | 14.45B | 12.43B | 11.96B |
| Cost of Revenue | 102.50B | 91.68B | 82.17B | 85.39B | 78.46B | 43.43B | 36.36B | 34.60B | 33.10B | 28.21B | 24.08B | 20.56B | 14.75B | 11.78B | 9.57B | 7.90B | 6.37B | 5.69B | 4.84B | 5.01B |
| Gross Profit | 68.01B | 58.95B | 60.70B | 54.89B | 50.83B | 72.56B | 57.93B | 63.78B | 53.42B | 44.03B | 39.49B | 30.35B | 29.89B | 25.08B | 19.06B | 14.76B | 11.48B | 8.77B | 7.59B | 6.96B |
| Gross Profit Ratio | 39.89% | 39.13% | 42.48% | 39.13% | 39.31% | 62.56% | 61.44% | 64.83% | 61.74% | 60.95% | 62.12% | 59.62% | 66.95% | 68.04% | 66.58% | 65.12% | 64.31% | 60.64% | 61.06% | 58.14% |
| Research & Development | 12.36B | 10.41B | 11.20B | 10.97B | 9.52B | 1.69B | 1.44B | 1.39B | 1.09B | 574.00M | 823.00M | 0.00 | 2.50B | 1.66B | 1.56B | 1.34B | 1.34B | 797.00M | 736.00M | 615.00M |
| General & Administrative | 0.00 | 0.00 | 4.72B | 5.44B | 3.40B | 2.75B | 2.46B | 2.32B | 1.77B | 1.79B | 1.40B | 0.00 | 18.78B | 15.34B | 1.53B | 1.40B | 926.00M | 495.00M | 684.00M | 703.00M |
| Selling & Marketing | 0.00 | 0.00 | 13.88B | 13.34B | 10.35B | 10.15B | 8.30B | 10.20B | 9.60B | 9.02B | 7.89B | 0.00 | 0.00 | 0.00 | 5.54B | 4.09B | 3.01B | 2.25B | 1.81B | 1.45B |
| SG&A | 28.37B | 24.11B | 22.82B | 24.14B | 18.97B | 12.89B | 10.75B | 12.52B | 11.37B | 10.82B | 9.29B | 0.00 | 18.78B | 15.34B | 7.07B | 5.49B | 3.94B | 2.75B | 2.50B | 2.15B |
| Other Expenses | -357.00M | -174.00M | -393.00M | -522.00M | -317.00M | 34.98B | 30.38B | 29.02B | 26.07B | 22.53B | 19.87B | 24.32B | -517.00M | 1.18B | 5.28B | 4.29B | 3.24B | 2.12B | 2.48B | 2.34B |
| Operating Expenses | 41.09B | 34.69B | 34.41B | 35.63B | 28.81B | 49.56B | 42.57B | 42.93B | 38.53B | 33.92B | 29.98B | 24.32B | 20.77B | 18.18B | 13.91B | 11.12B | 8.52B | 5.67B | 5.71B | 5.10B |
| Cost & Expenses | 143.59B | 126.37B | 116.58B | 121.02B | 107.27B | 92.99B | 78.94B | 77.53B | 71.62B | 62.14B | 54.06B | 44.87B | 35.52B | 29.96B | 23.48B | 19.02B | 14.89B | 11.36B | 10.55B | 10.11B |
| Interest Income | 757.00M | 688.00M | 495.00M | 325.00M | 796.00M | 494.00M | 573.00M | 601.00M | 387.00M | 343.00M | 267.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.30B | 1.20B | 1.64B | 3.33B | 1.96B | 1.05B | 568.00M | 410.00M | 555.00M | 1.10B | 1.17B | 0.00 | 0.00 | 0.00 | 1.21B | 335.00M | 223.00M | 251.00M | 245.00M | 210.00M |
| Depreciation & Amortization | 7.23B | 7.13B | 7.25B | 6.97B | 5.99B | 5.41B | 3.75B | 3.02B | 2.87B | 2.01B | 1.85B | 1.58B | 1.27B | 1.34B | 1.12B | 969.00M | 823.00M | 779.00M | 716.00M | 712.00M |
| EBITDA | 34.14B | 31.39B | 32.98B | 26.22B | 28.01B | 29.85B | 20.48B | 24.37B | 17.51B | 12.21B | 10.74B | 9.24B | 9.44B | 7.13B | 6.02B | 4.49B | 3.71B | 2.80B | 2.37B | 2.47B |
| EBITDA Ratio | 20.03% | 20.84% | 23.09% | 18.69% | 21.66% | 25.74% | 21.72% | 24.77% | 20.24% | 16.90% | 16.89% | 18.14% | 21.15% | 19.34% | 21.03% | 19.83% | 20.77% | 19.35% | 19.05% | 20.62% |
| Operating Income | 26.92B | 24.26B | 26.29B | 19.25B | 22.02B | 23.00B | 15.36B | 20.85B | 14.89B | 10.11B | 9.51B | 6.03B | 9.12B | 6.91B | 5.14B | 3.64B | 2.96B | 3.10B | 1.88B | 1.85B |
| Operating Income Ratio | 15.79% | 16.10% | 18.40% | 13.73% | 17.03% | 19.83% | 16.29% | 21.19% | 17.21% | 13.99% | 14.96% | 11.84% | 20.44% | 18.73% | 17.97% | 16.05% | 16.59% | 21.43% | 15.11% | 15.47% |
| Total Other Income/Expenses | -1.02B | 4.12B | -2.30B | -4.30B | 1.80B | 1.22B | 759.00M | 390.00M | -434.00M | -683.00M | -1.43B | 1.91B | -699.00M | -867.00M | -1.45B | -404.00M | -223.00M | -1.33B | -507.00M | -336.00M |
| Income Before Tax | 25.90B | 28.38B | 23.99B | 14.95B | 23.82B | 23.31B | 16.12B | 21.24B | 14.46B | 9.42B | 8.09B | 7.94B | 8.43B | 6.04B | 3.70B | 3.23B | 2.74B | 1.77B | 1.37B | 1.52B |
| Income Before Tax Ratio | 15.19% | 18.84% | 16.79% | 10.66% | 18.42% | 20.09% | 17.09% | 21.59% | 16.71% | 13.04% | 12.72% | 15.60% | 18.87% | 16.38% | 12.92% | 14.27% | 15.34% | 12.23% | 11.03% | 12.67% |
| Income Tax Expense | 5.88B | 5.12B | 1.94B | 3.20B | 5.30B | 5.64B | 1.29B | 5.71B | 2.59B | 1.06B | 1.19B | 1.13B | 1.06B | 741.00M | 666.00M | 613.00M | 324.00M | 243.00M | 192.00M | 213.00M |
| Net Income | 19.60B | 18.07B | 21.34B | 11.77B | 18.49B | 17.76B | 14.88B | 15.23B | 11.49B | 8.04B | 6.54B | 6.53B | 7.11B | 5.05B | 3.03B | 2.58B | 2.34B | 1.52B | 1.22B | 1.33B |
| Net Income Ratio | 11.50% | 11.99% | 14.93% | 8.39% | 14.30% | 15.31% | 15.78% | 15.48% | 13.28% | 11.12% | 10.28% | 12.82% | 15.92% | 13.70% | 10.59% | 11.37% | 13.09% | 10.54% | 9.77% | 11.13% |
| EPS | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 14.87 | 11.22 | 7.85 | 6.38 | 6.37 | 6.95 | 4.93 | 2.96 | 2.73 | 2.48 | 3.24 | 2.58 | 2.83 |
| EPS Diluted | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 14.87 | 11.22 | 7.85 | 6.38 | 6.37 | 6.95 | 4.93 | 2.96 | 2.73 | 2.48 | 3.24 | 2.58 | 2.83 |
| Weighted Avg Shares Out | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 471.05M | 471.05M | 471.05M |
| Weighted Avg Shares Out (Dil) | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 471.05M | 471.05M | 471.05M |
Source: https://incomestatements.info
Category: Stock Reports